for males ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
completion around
Principal Investigator
by Hala Borno, MD
Headshot of Hala Borno
Hala Borno



This clinical trial studies a digital platform, the supportive therapy in androgen deprivation (STAND-T), in achieving equity for men undergoing treatment with androgen deprivation therapy for prostate cancer. STAND-T is a digital platform that provides prostate health information, evidence-based materials and resources. STAND-T may help improve health, address symptoms, and promote equity in men with prostate cancer.

Official Title

Leveraging Technology (STAND-T) to Achieve Equity for Men With Prostate Cancer on Androgen Deprivation Therapy



  1. To assess study feasibility of the STAND-T program at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) and Zuckerberg San Francisco General Hospital and Trauma Center (ZSFG) genitourinary (GU) medical, surgical, and radiation oncology practices.


  1. To measure preliminary estimates of acceptability and usage of a digital platform, STAND-T.


  1. To describe diet (e.g., fruit and vegetable intake), lifestyle (e.g., moderate to vigorous exercise, smoking status), clinical (symptoms e.g., fatigue), and health related quality of life (QoL) outcomes (e.g., sleep disturbance), physiologic measures (body mass index, BMI) at baseline and change in these metrics from baseline to 3 months post-intervention.


Patients review educational material and resources via online STAND-T platform. Patients also receive interactive text messages for 3 months.

After completion of study, patients are followed up at 3 months.


Prostate Cancer, Health Technologies, Prostatic Neoplasms, STAND-T platform, Health services research (STAND-T, text messages)


You can join if…

Open to males ages 18 years and up

  • Age >18 years
  • Ability to understand study procedures and to comply with them for the entire length of the study
  • Ability of individual or legal guardian/representative to understand an informed consent document and the willingness to sign it
  • Adenocarcinoma of the prostate
  • Current or planned anti-androgen therapy (ADT) (oral or injection) with gonadotropin-releasing hormone (GnRH) antagonist or luteinizing hormone releasing hormone (LHRH) agonist
  • Life expectancy duration of 6 months or longer from date of study consent
  • Prior and concurrent radiation is allowed
  • Treatment with concurrent androgen signaling inhibitors is allowed
  • < 75 minutes/week of vigorous aerobic exercise based on Godin survey or < 2 days per week of vigorous activity

You CAN'T join if...

  • Contraindication to any study-related procedure or assessment
  • Planned surgery/chemotherapy/immunotherapy/parp inhibitor treatment during the study period
  • Prior and concurrent investigational therapies
  • Unable to read/speak English
  • Unable to access the Internet
  • Has seen an exercise counselor in the past 6 months for prostate or cardiovascular health
  • Has seen a dietary counselor in the past 6 months for prostate or cardiovascular health


  • Zuckerberg San Francisco General Hospital accepting new patients
    San Francisco California 94110 United States
  • UCSF accepting new patients
    San Francisco California 94142 United States

Lead Scientist at UCSF

  • Hala Borno, MD
    Dr. Hala Borno is faculty at UCSF and an Associate Professor in the Department of Medicine and Division of Hematology/Oncology and co-Medical Director of the Genitourinary Medical Oncology Clinic at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) at the University of California San Francisco (UCSF).


accepting new patients
Start Date
Completion Date
University of California, San Francisco
Study Type
Expecting 50 study participants
Last Updated